Potentially Reversible and Recognizable Acute Encephalopathic Syndromes: Disease Categorization and MRI Appearances

References

1. 1.↵
   1. Page M

   . The British Medical Association Illustrated Medical Dictionary: A Dorling Kindersley Book. Dorling-Kindersley;2002;199
2. 2.↵
   1. Huang H,
   2. Koksel Y,
   3. McKinney Z, et al

   . Building a predictive analytics foundation to assess radiologically identifiable encephalopathies. In: Proceedings of the Annual Meeting of the American Society of Neuroradiology, Vancouver, British Columbia, Canada. June 2–7, 2018
3. 3.↵
   1. Van der Worp HB,
   2. Van Gijn J

   . Acute ischemic stroke. N Engl J Med 2007;357:572–79 doi:10.1056/NEJMcp072057 pmid:17687132

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Singhal AB,
   2. Hajj-Ali RA,
   3. Topcuoglu MA, et al

   . Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol 2011;68:1005–12 doi:10.1001/archneurol.2011.68 pmid:21482916

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Lee MJ,
   2. Cha J,
   3. Choi HA, et al

   . Blood–brain barrier breakdown in reversible cerebral vasoconstriction syndrome: implications for pathophysiology and diagnosis. Ann Neurol 2017;81:454–66 doi:10.1002/ana.24891 pmid:28195428

   CrossRefPubMed
6. 6.↵
   1. Rocha EA,
   2. Topcuoglu MA,
   3. Silva GS, et al

   . RCVS₂ score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology 2019;92:e639–47 doi:10.1212/WNL.0000000000006917 pmid:30635475

   CrossRefPubMed
7. 7.↵
   1. Arena JE,
   2. Rabinstein AA

   . Transient global amnesia. Mayo Clin Proc 2015;90:264–72 doi:10.1016/j.mayocp.2014.12.001 pmid:25659242

   CrossRefPubMed
8. 8.↵
   1. Enzinger C,
   2. Thimary F,
   3. Kapeller P, et al

   . Transient global amnesia: diffusion-weighted imaging lesions and cerebrovascular disease. Stroke 2008;39:2219–25 doi:10.1161/STROKEAHA.107.508655 pmid:18583561

   Abstract/FREE Full Text
9. 9.↵
   1. Sander K,
   2. Sander D

   . New insights into transient global amnesia: recent imaging and clinical findings. Lancet Neurol 2005;4:437–44 doi:10.1016/S1474-4422(05)70121-6 pmid:15963447

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Burrus TM,
    2. Wijdicks EF,
    3. Rabinstein AA

    . Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology 2009;73:66–70 doi:10.1212/WNL.0b013e3181aaea1b pmid:19564586

    Abstract/FREE Full Text
11. 11.↵
    1. Hoffman O,
    2. Weber RJ

    . Pathophysiology and treatment of bacterial meningitis. Ther Adv Neurol Disord 2009;2:1–7 doi:10.1177/1756285609337975 pmid:21180625

    CrossRefPubMed
12. 12.↵
    1. Mohan S,
    2. Jain KK,
    3. Arabi M, et al

    . Imaging of meningitis and ventriculitis. Neuroimaging Clin N Am 2012;22:557–83 doi:10.1016/j.nic.2012.04.003 pmid:23122257

    CrossRefPubMed
13. 13.↵
    1. McKinney AM,
    2. Palmer C,
    3. Short J, et al

    . Utility of fat-suppressed FLAIR and subtraction imaging in detecting meningeal abnormalities. Neuroradiology 2006;48:881–85 doi:10.1007/s00234-006-0145-5 pmid:16969672

    CrossRefPubMed
14. 14.↵
    1. Galassi W,
    2. Phuttharak W,
    3. Hesselink JR, et al

    . Intracranial meningeal disease: comparison of contrast-enhanced MR imaging with fluid attenuated inversion recovery and fat-suppressed T1-weighted sequences. AJNR Am J Neuroradiol 2005;26:553–59 pmid:15760865

    Abstract/FREE Full Text
15. 15.↵
    1. Küker W,
    2. Nägele T,
    3. Schmidt F, et al

    . Diffusion-weighted MRI in herpes simplex encephalitis: a report of three cases. Neuroradiology 2004;46:122–25 doi:10.1007/s00234-003-1145-3 pmid:14747879

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Piantadosi A,
    2. Rubin DB,
    3. McQuillen DP, et al

    . Emerging cases of Powassan virus encephalitis in New England: clinical presentation, imaging, and review of the literature. Clin Infect Dis 2016;62:707–13 doi:10.1093/cid/civ1005 pmid:26668338

    CrossRefPubMed
17. 17.↵
    1. Ozutemiz C,
    2. Roshan SK,
    3. Kroll NJ, et al

    . Acute toxic leukoencephalopathy: etiologies, imaging findings, and outcomes in 101 patients. AJNR Am J Neuroradiol 2019;40:267–75 doi:10.3174/ajnr.A5947

    Abstract/FREE Full Text
18. 18.↵
    1. De Oliveira AM,
    2. Paulino MV,
    3. Vieira APF, et al

    . Imaging patterns of toxic and metabolic brain disorders. Radiographics 2019;39:1672–95 doi:10.1148/rg.2019190016 pmid:31589567

    CrossRefPubMed
19. 19.↵
    1. Chokshi FH,
    2. Aygun N,
    3. Mullins ME

    . Imaging of acquired metabolic and toxic disorders of the basal ganglia. Semin Ultrasound CT MR 2014;35:75–84 doi:10.1053/j.sult.2013.09.006 pmid:24745885

    CrossRefPubMed
20. 20.↵
    1. McKinney AM,
    2. Short J,
    3. Truwit CL, et al

    . Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189:904–12 doi:10.2214/AJR.07.2024 pmid:17885064

    CrossRefPubMedWeb of Science
21. 21.↵
    1. McKinney AM,
    2. Jagadeesan BD,
    3. Truwit CL

    . Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema. AJR Am J Roentgenol 2013;201:631–38 doi:10.2214/AJR.12.9677 pmid:23971457

    CrossRefPubMed
22. 22.↵
    1. McKinney AM,
    2. Sarikaya B,
    3. Gustafson C, et al

    . Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:896–903 doi:10.3174/ajnr.A2886

    Abstract/FREE Full Text
23. 23.↵
    1. Karia SJ,
    2. Rykken JB,
    3. McKinney ZJ, et al

    . Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2016;37:415–22 doi:10.3174/ajnr.A4563 pmid:26564441

    Abstract/FREE Full Text
24. 24.↵
    1. McKinney AM,
    2. Kieffer SA,
    3. Paylor RT, et al

    . Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. Am J Roentgenol 2009;193:192–206 doi:10.2214/AJR.08.1176 pmid:9542414

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Koksel Y,
    2. Ozutemiz C,
    3. Rykken J, et al

    . “CHOICES”: An acronym to aid in delineating potential causes of non-metabolic, non-infectious acute toxic leukoencephalopathy. Eur J Radiol Open 2019;6:243–57 doi:10.1016/j.ejro.2019.06.005 pmid:31309133

    CrossRefPubMed
26. 26.↵
    1. Özütemiz C,
    2. Roshan SK,
    3. Kroll NJ, et al

    . Concomitant acute toxic leukoencephalopathy and posterior reversible encephalopathy syndrome. J Neuroimaging 2018;28:535–41 doi:10.1111/jon.12526 pmid:29797465

    CrossRefPubMed
27. 27.↵
    1. Beitinjaneh A,
    2. McKinney AM,
    3. Cao Q, et al

    . Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300–08 doi:10.1016/j.bbmt.2010.04.003 pmid:20399878

    CrossRefPubMed
28. 28.↵
    1. Arbelaez A,
    2. Castillo M,
    3. Mukherji SK

    . Diffusion-weighted MR imaging of global cerebral anoxia. AJNR Am J Neuroradiol 1999;20:999–1007 pmid:10445435

    Abstract/FREE Full Text
29. 29.↵
    1. Iqbal S,
    2. Clower JH,
    3. Hernandez SA, et al

    . A review of disaster-related carbon monoxide poisoning: surveillance, epidemiology, and opportunities for prevention. Am J Public Health 2012;102:1957–63 doi:10.2105/AJPH.2012.300674 pmid:22897556

    CrossRefPubMed
30. 30.↵
    1. Lo CP,
    2. Chen SY,
    3. Lee KW, et al

    . Brain injury after acute carbon monoxide poisoning: early and late complications. Am J Roentgenol 2007;189:205–11 doi:10.2214/AJR.07.2425 pmid:17885032

    CrossRefPubMed
31. 31.↵
    1. Zuccoli G,
    2. Siddiqui N,
    3. Cravo I, et al

    . Neuroimaging findings in alcohol-related encephalopathies. AJR Am J Roentgenol 2010;195:1378–84 doi:10.2214/AJR.09.4130 pmid:21098198

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Kim E,
    2. Na DG,
    3. Kim EY, et al

    . MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol 2007;28:1652–58 doi:10.3174/ajnr.A0655 pmid:17885234

    Abstract/FREE Full Text
33. 33.↵
    1. Khanipour Roshan S,
    2. Spano AD,
    3. McKinney AM, et al

    . Potentially reversible acute cerebellar toxicity associated with Minnelide. Neuroradiology 2017;59:419–21 doi:10.1007/s00234-017-1809-z pmid:28303374

    CrossRefPubMed
34. 34.↵
    1. Tada H,
    2. Takanashi J,
    3. Barkovich AJ, et al

    . Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004;63:1854–58 doi:10.1212/01.wnl.0000144274.12174.cb pmid:15557501

    Abstract/FREE Full Text
35. 35.↵
    1. Szólics M,
    2. Chaudhry M,
    3. Ljubisavljevic M, et al

    . Neuroimaging findings in a case of fluoxetine overdose. J Neuroradiol 2012;39:254–57 doi:10.1016/j.neurad.2011.10.006 pmid:22197403

    CrossRefPubMed
36. 36.↵
    1. Lancaster E

    . The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol 2016;12:1–13 doi:10.3988/jcn.2016.12.1.1 pmid:26754777

    CrossRefPubMed
37. 37.↵
    1. Oyanguren B,
    2. Sánchez V,
    3. González FJ, et al

    . Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol 2013;20:1566–70 doi:10.1111/ene.12249 pmid:23941332

    CrossRefPubMed
38. 38.↵
    1. Ruzek KA,
    2. Campeau NG,
    3. Miller GM

    . Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol 2004;25:210–13 pmid:14970019

    Abstract/FREE Full Text
39. 39.↵
    1. Kim DM,
    2. Lee IH,
    3. Song CJ

    . Uremic encephalopathy: MR imaging findings and clinical correlation. AJNR Am J Neuroradiol 2016;37:1604–09 doi:10.3174/ajnr.A4776 pmid:27127003

    Abstract/FREE Full Text
40. 40.↵
    1. Vanholder R,
    2. De Smet R,
    3. Glorieux G, et al

    ; European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934–43 doi:10.1046/j.1523-1755.2003.00924.x pmid:12675874

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Kumar G,
    2. Goyal MK

    . Lentiform fork sign: a unique MRI picture: is metabolic acidosis responsible? Clin Neurol Neurosurg 2010;112:805–12 doi:10.1016/j.clineuro.2010.06.006 pmid:20615611

    CrossRefPubMed
42. 42.↵
    1. McKinney AM,
    2. Lohman BD,
    3. Sarikaya B, et al

    . Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. AJNR Am J Neuroradiol 2010;31:1471–79 doi:10.3174/ajnr.A2112 pmid:20448015

    Abstract/FREE Full Text
43. 43.↵
    1. Blauenfeldt RA,
    2. Olesen SS,
    3. Hansen JB, et al

    . Abnormal brain processing in hepatic encephalopathy: evidence of cerebral reorganization? Eur J Gastroenterol Hepatol 2010;22:1323–30 doi:10.1097/MEG.0b013e32833d4717

    CrossRefPubMed
44. 44.↵
    1. Benson JC,
    2. Payabvash S,
    3. Thalken GL, et al

    . Delineation of microhemorrhage in acute hepatic encephalopathy using susceptibility-weighted imaging. Eur J Radiol 2016;85:629–34 doi:10.1016/j.ejrad.2015.12.025 pmid:26860677

    CrossRefPubMed
45. 45.↵
    1. Koksel Y,
    2. Benson J,
    3. Huang H, et al

    . Review of diffuse cortical injury on diffusion-weighted imaging in acutely encephalopathic patients with an acronym: “CRUMPLED.” Eur J Radiol Open 2018;5:194–201 doi:10.1016/j.ejro.2018.10.004 pmid:30456218

    CrossRefPubMed
46. 46.↵
    1. Bartleson JD,
    2. Krecke KN,
    3. O’Neill BP, et al

    . Reversible, strokelike migraine attacks in patients with previous radiation therapy. Neuro Oncol 2003;5:121–27 doi:10.1093/neuonc/5.2.121 pmid:12672284

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Kerklaan JP,
    2. Lycklama Á Nijeholt GJ,
    3. Wiggenraad RGJ, et al

    . SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol 2011;258:1098–104 doi:10.1007/s00415-010-5892-x pmid:21373901

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Khanipour Roshan S,
    2. Salmela MB,
    3. McKinney AM

    . Susceptibility-weighted imaging in stroke-like migraine attacks after radiation therapy syndrome. Neuroradiology 2015;57:1103–09 doi:10.1007/s00234-015-1567-8 pmid:26242361

    CrossRefPubMed
49. 49.↵
    1. Oh J,
    2. Choi SH,
    3. Lee E, et al

    . Application of 3D fast spin-echo T1 black-blood imaging in the diagnosis and prognostic prediction of patients with leptomeningeal carcinomatosis. AJNR Am J Neuroradiol 2018;39:1453–59 doi:10.3174/ajnr.A5721 pmid:30002052

    Abstract/FREE Full Text
50. 50.↵
    1. Tsuchiya K,
    2. Katase S,
    3. Yoshino A, et al

    . FLAIR MR imaging for diagnosing intracranial meningeal carcinomatosis. AJR Am J Roentgenol 2001;176:1585–88 doi:10.2214/ajr.176.6.1761585 pmid:11373237

    CrossRefPubMed
51. 51.↵
    1. Cianfoni A,
    2. Caulo M,
    3. Cerase A, et al

    . Seizure-induced brain lesions: a wide spectrum of variably reversible MRI abnormalities. Eur J Radiol 2013;82:1964–72 doi:10.1016/j.ejrad.2013.05.020 pmid:23787273

    CrossRefPubMed
52. 52.↵
    1. Cole AJ

    . Status epilepticus and periictal imaging. Epilepsia 2004;45:72–74 doi:10.1111/j.0013-9580.2004.04014.x pmid:15281962

    CrossRefPubMed